TetraLogic Pharmaceuticals (TLOG) Announces Publication Of Preclinical Characterization Of Birinapant
4/1/2014 10:20:56 AM
MALVERN, Pa., April 1, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors.
Help employers find you! Check out all the jobs and post your resume.
comments powered by